14-05-2020
Jarun Ontakrai/ Shutterstock.com
Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Natera, Illumina, prenatal, testing, patent, infringement, licence, litigation, settle, agree, sequencing, platform, NPIT
Invitae claims Natera infringed DNA patents
13-05-2021
Illumina to acquire Jeff Bezos-backed cancer testing company
23-09-2020
Teva to face inhaler infringement allegations in UK court
03-06-2020
Natera sues ArcherDX for oncology patent infringement
29-01-2020
English High Court upholds Sequenom patent for prenatal test
18-06-2019
